YouTube video by Vincent Bonnevialle

Click to view the official SEC document.

YouTube video by Viva La Dirt League

Click to view the official SEC document.

YouTube video by The Leaving Trains - Topic

YouTube video by Fearless Records

Our first ever Java stream on AspiriFridays is happening THE FRIDAY BEFORE #AspireConf! Marshal, a long time Aspire contributor, is going to take us through the new Java integration in the Community…

Click to view the official SEC document.

Click to view the official SEC document.

Orthofix (NASDAQ:OFIX) reported second quarter 2026 net sales of $210.9 million, up 3.8% reported and 4.7% on a pro forma constant currency basis versus 2025, driven by double‑digit constant currency growth in Global Spine Fixation and Global Limb Reconstruction and 3% growth in Therapeutic Solutions.GAAP gross margin was 71.0% and non‑GAAP adjusted EBITDA was $20.1 million (9.6% of pro forma net sales), while reported net loss was $15.8 million, or $(0.39) per share. Cash, cash equivalents, and restricted cash totaled $104.4 million on June 30, 2026. Following Medicare reimbursement restoration for non‑invasive bone growth stimulators and Q2 performance, Orthofix raised its full‑year 2026 pro forma guidance, now expecting net sales of $845–$855 million and adjusted EBITDA of $95–$98 million, implying margin expansion versus 2025.

The Johnson& Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every...

Medicare reversed a pay cut for Orthofix devices, restoring revenue outlook and boosting the stock on improved earnings visibility.

Orthofix Medical (OFIX 13.46%), a medical device and biologics company specializing in spinal, orthopedic, and bone growth products, reported results for Q2 2025 that modestly beat expectations on both GAAP earnings and non-GAAP revenue. The company announced its earnings for the quarter ended June 30 on August 5, 2025. GAAP revenue totaled $203.1 million for Q2 2025, exceeding the analyst estimate of $196.19 million (non-GAAP). Meanwhile, net loss per share narrowed to $(0.36) on a reported (GAAP) basis, better than the expected $(0.49) (GAAP). Despite ongoing reported losses, the quarter saw improvement in margins (non-GAAP pro forma adjusted gross margin of 72.7%), positive free cash flow of $4.5 million, and continued new product execution.